Novartis Fends Off US Fingolimod Competition – For Now
No Gilenya Generics Expected ‘For At Least The Next Two Years’ In US, Originator Says
The latest decision in US litigation with HEC Pharma over multiple sclerosis treatment Gilenya means that generics will be kept off the market for at least two years, according to originator Novartis.
